SONN (Sonnet BioTherapeutics Holdings) Insider Ownership: 1.90 % (As of Sep. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SONN Sonnet BioTherapeutics Holdings Inc SONN
28 GF Score
Price $1.26
View Full Analysis

What is Sonnet BioTherapeutics Holdings Insider Ownership?

Sonnet BioTherapeutics Holdings SONN 28 Insider Ownership is 1.90 % as of Sep. 13, 2026. GuruFocus rates SONN with a GF Score™ of 28/100.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sonnet BioTherapeutics Holdings's insider ownership is 1.90%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sonnet BioTherapeutics Holdings's Institutional Ownership is 0.54%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sonnet BioTherapeutics Holdings's Float Percentage Of Total Shares Outstanding is 99.82%.

Sonnet BioTherapeutics Holdings Insider Ownership Historical Data

* Premium members only.

The historical data trend for Sonnet BioTherapeutics Holdings's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sonnet BioTherapeutics Holdings Insider Ownership Chart

Sonnet BioTherapeutics Holdings Historical Data

The historical data trend for Sonnet BioTherapeutics Holdings can be seen below:

2025-02-28 2025-03-31 2025-04-30 2025-05-31 2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30
Insider Ownership 1.56 1.56 1.56 1.51 1.51 2.07 1.90 1.90 1.90 1.90
SONN
28GF Score
Sonnet BioTherapeutics Holdings Inc SONN
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sonnet BioTherapeutics Holdings Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 1.90 % mean?
Sonnet BioTherapeutics Holdings (SONN) has a Insider Ownership of 1.90 % as of Sep. 13, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Sonnet BioTherapeutics Holdings and its competitors.
Is Sonnet BioTherapeutics Holdings' Insider Ownership too high?
Sonnet BioTherapeutics Holdings' current Insider Ownership is 1.90 %. Overall, Sonnet BioTherapeutics Holdings has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Sonnet BioTherapeutics Holdings' Insider Ownership compare to CING and BOLD?
Sonnet BioTherapeutics Holdings' Insider Ownership of 1.90 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Sonnet BioTherapeutics Holdings and its competitors. Sonnet BioTherapeutics Holdings's current Insider Ownership is 1.90 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonnet BioTherapeutics Holdings stock overvalued right now?
Sonnet BioTherapeutics Holdings (SONN) has a current Insider Ownership of 1.90 %. The current Insider Ownership is 1.90 %. Sonnet BioTherapeutics Holdings' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Sonnet BioTherapeutics Holdings (SONN), the current Insider Ownership is 1.90 % as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sonnet BioTherapeutics Holdings Business Description

Address 100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
28GF Score

Get the complete analysis for SONN

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price